TNF-alpha processing inhibitor

Drug Profile

TNF-alpha processing inhibitor

Alternative Names: TAPI - Amgen; TNF-alpha protease enzyme inhibitor; Tumour necrosis factor-alpha protease inhibitor

Latest Information Update: 23 Jun 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories
  • Mechanism of Action Tumour necrosis factor-alpha convertase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 23 Jun 2000 No-Development-Reported for Inflammation in USA (Unknown route)
  • 21 Apr 1999 Immunex has exclusively licensed its TNF-alpha converting enzyme technology to Wyeth-Ayerst
  • 14 Feb 1997 Preclinical development for Inflammation in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top